Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency

The purpose of this study is to evaluate the efficacy of cisplatin based regimen to patients with advanced pancreatic cancer and homologous recombination deficiency.

Trial Details

NCT ID
NCT06095141
Phase
PHASE2 / PHASE3
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Cisplatin
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Ability to understand and the willingness to sign a written informed consent document.
  • Age ≥ 18 years and ≤ 80 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  • Histologically or cytologically confirmed advanced pancreas adenocarcinoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →